Search

everythinglearnresearchcommunity

for

Search:↓

The user plans to switch from minoxidil to finasteride or dutasteride for hair loss, while managing hormones with aromatase inhibitors and SHBG blockers. They seek advice on the best options for these treatments, considering past side effects and future therapies.

A woman has been struggling with hair loss for over 12 years and is frustrated with doctors refusing to prescribe finasteride due to potential birth defects and unproven breast cancer risk. She's considering self-treatment or permanent birth control, after being offered only minoxidil, PRP therapy, and weaker natural supplements like Saw Palmetto.

Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.

RU58841 is considered effective by some users, but finasteride and minoxidil are commonly used with varying dosages to manage side effects. Users report different experiences with treatments like pyrilutamide, fluridil, and RU58841, with some seeing results and others not.

Exercise improved minor side effects of finasteride, such as reduced ejaculatory volume and depression, and also helped with gyno. Running and push-ups were particularly effective, leading to increased ejaculatory volume and improved mental clarity.

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

The conversation discusses hair loss treatments, specifically Regenera stem cells and exosomes from 'Cellgenic' umbilical cord donors. The user has been using topical minoxidil 5% and 0.001% estradiol for a year without seeing effects, and another user mentions the importance of microneedling.

A double-blind clinical study that found ingestion of tocotrienols resulted in a 34.5% increase in hair regrowth compared to the placebo group, and discussion about potential side effects and cost of supplementation with vitamin E pills. The conversation noted that it may be more effective than commonly used treatments like minoxidil and finasteride.

The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.

Topical spiro's effectiveness on androgens is discussed. User tried oral DUT, oral Min, keto/nizoral, and RU but experienced worsening hair loss and chest pains. Suggestion given to increase dutasteride and oral minoxidil dosage before considering spironolactone.

The user experienced significant hair regrowth after 5 months on 0.5mg of finasteride, with no side effects except mild, temporary testicular pain. Minoxidil was used for 5 years without noticeable results, and dermastamping and rosemary oil were also mentioned as part of other users' routines.

The user experienced significant hair regrowth using finasteride, starting with 1mg five times a week and later reducing to 0.5mg six times a week for maintenance. They reported some initial side effects, like minor pain and watery semen, but no major issues, and attributed additional improvements to lifestyle changes.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Spironolactone is more potent and lowers testosterone and DHT, while dutasteride only impacts DHT. For female hair loss, checking hormones and considering treatments like oral minoxidil, spironolactone, or topical minoxidil is recommended.

A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

Bimatoprost 1% and 3% solutions showed better hair regrowth than minoxidil 5%. The user plans to test a homemade bimatoprost solution on their scalp and share results.

Using PRP or Exosome treatments alongside Finasteride/Dutasteride and Minoxidil may not significantly enhance results. Dutasteride and oral Minoxidil are considered more effective options.

The user experienced erectile dysfunction from oral finasteride and is considering alternatives like topical high-dose finasteride, RU58841, topical Latanoprost, and oral Minoxidil. Blood tests showed changes in testosterone and DHT levels, and the endocrinologist advised stopping finasteride.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

A 26 year old female diagnosed with androgenetic alopecia who is interested in treatments such as spironolactone, finasteride and Minoxidil to help her hair loss but is worried about side effects like muscle gain, sex drive and effectiveness.

The user is concerned about mixing Pantostin (with Alfatradiol) and Finasteride in a topical solution, fearing a potential toxic reaction or ineffectiveness. They seek advice on whether this combination is safe.

A 32-year-old male used 1.25mg oral finasteride daily and 1ml topical minoxidil twice daily for 24 weeks, experiencing improved skin and hair growth with initial side effects that resolved after three weeks. He plans to try dermastamping to address a stubborn cowlick area.

A user shared progress pictures showing baby hairs appearing on their NW7 scalp after 4.5 months of using Propecia (finasteride) and minoxidil. They are hopeful these baby hairs will lead to full coverage.